Matt Montefusco says Johnson & Johnson's (JNJ) pharma business has performed exceptionally, but the company needs to focus more on its med-tech innovation to keep up with competition. However, it's the company's legal headwinds he believes could be its biggest challenge. Lee Brown also takes a deeper look into earnings to determine other financial headwinds that could swirl off future reports.